This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Jan 2013

Additional testing completed on Alzheimer's disease biomarker

Navidea has announced completion of tests into the impact of mass doses of its NAV4694 biomarker on PET scans of patients with Alzheimer's.

Biopharma company Navidea Biopharmaceuticals has announced the completion of a study into its new radiopharmaceutical NAV4694, which is designed to be used as a biomarker for visual detection of substances used in the diagnosis of Alzheimer's disease.

The study was designed by partner firm AstraZeneca to assess the effects that different amounts of the biomarker have on the safety and efficacy of Positron Emission Tomography (PET) scanning in patients with the neuro-degenerative condition.

Comparing patients to health controls, evaluations were completed on two mass doses of the radiogland and the effects they had on image quality.
"We are very pleased to have completed this study addressing some of the fundamental requirements of diagnostic imaging agents seeking approval," said Cornelia Reininger, managing director of Navidea and the company's chief medical officer.

"We continue to make exciting progress with NAV4694, which has demonstrated important performance characteristics that we believe position it as a true 'best-in-class' second generation agent to aid in the diagnosis of Alzheimer's disease."

Related News